iX Biopharma (SGX:42C) EV-to-FCF: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:42C iX Biopharma Ltd SGX:42C
36 GF Score
Price S$0.55
GF Value S$0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is iX Biopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, iX Biopharma's Enterprise Value is S$585.27 Mil. iX Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was S$0.00 Mil. Therefore, iX Biopharma's EV-to-FCF for today is .

The historical rank and industry rank for iX Biopharma's EV-to-FCF or its related term are showing as below:

SGX:42C' s EV-to-FCF Range Over the Past 10 Years
Min: -149.21   Med: -10.32   Max: -0.61
Current: -149.21

During the past 12 years, the highest EV-to-FCF of iX Biopharma was -0.61. The lowest was -149.21. And the median was -10.32.

SGX:42C's EV-to-FCF is ranked worse than
100% of 569 companies
in the Drug Manufacturers industry
Industry Median: 21.6 vs SGX:42C: -149.21

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-07), iX Biopharma's stock price is S$0.545. iX Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was S$-0.003. Therefore, iX Biopharma's PE Ratio (TTM) for today is At Loss.


iX Biopharma  (SGX:42C) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

iX Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.545/-0.003
=At Loss

iX Biopharma's share price for today is S$0.545.
iX Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-0.003.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


iX Biopharma EV-to-FCF Related Terms


iX Biopharma EV-to-FCF Historical Data

* Premium members only.

The historical data trend for iX Biopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iX Biopharma EV-to-FCF Chart

iX Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.57 38.78 -8.09 -3.80 -4.86

iX Biopharma Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -4.86 0.00 0.00

SGX:42C vs ZTS, UTHR, VTRS: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iX Biopharma EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where iX Biopharma's EV-to-FCF falls into.


SGX:42C
36GF Score
iX Biopharma Ltd SGX:42C
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iX Biopharma EV-to-FCF Calculation

iX Biopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=585.267/0
=

iX Biopharma's current Enterprise Value is S$585.27 Mil.
iX Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is iX Biopharma (SGX:42C) Overvalued in 2026?

Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued. The current stock price of S$0.55 is trading 1716.7% above its estimated GF Value™ of S$0.03. GuruFocus considers iX Biopharma to be Significantly Overvalued.

Key valuation signals for SGX:42C:

  • EV-to-FCF:
  • GF Value™: S$0.03 vs. price of S$0.55 (1716.7% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iX Biopharma Business Description

Address 1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score

Get the complete analysis for SGX:42C

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.55
Price
S$0.03
GF Value